Pharmanutra PHN Stock: price and insider trades · Italy
Pharmanutra PHN: what insiders have been doing
Insider filings for Pharmanutra PHN are scarce in the Consob feed, the latest one published on 8 September 2025. This page will fill in as new trades are disclosed. This summary is built from Consob disclosures alone and does not predict where the share price will go.
Insider Decl.
12
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 8,011 of 26,897 companies
61.7
score / 100
Value38
Quality85
FCF yld2.1%
Earn yld2.6%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€81.90
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.2x
PER (forward)26.7x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€784.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 8 September 2025
Declarations12 total
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
12 of 12 declarations
About Pharmanutra PHN
Pharmanutra PHN is a company specialized in the health and pharmaceutical sector, providing innovative products for well-being. It is listed on the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
